S8 Ep78: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

OncLive® On Air

English - November 06, 2023 19:45 - 11 minutes - 10.8 MB - ★★★★ - 19 ratings
Health & Fitness Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: S8 Ep77: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Next Episode: S8 Ep79: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.